Li Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Li Liu has a total of 106 co-authors. Here are the top co-authors by number of shared publications:
Bangting Wang
Digestive Endoscopy Department, The First Affiliated Hospital With Nanjing Medical University and Jiangsu Province Hospital, Nanjing, China
6 shared publicationsYan Wang
Department of Gastroenterology Jiangsu Province Hospital and the First Affiliated Hospital with Nanjing Medical University Nanjing China
6 shared publicationsJiankun Wang
Department of Geriatric Gastroenterology Jiangsu Province Hospital and the First Affiliated Hospital with Nanjing Medical University Nanjing China
5 shared publicationsMin Fu
Gastroenterology Department the Fourth Affiliated Hospital with Nanjing Medical University Nanjing China
5 shared publicationsMin Wang
Department of Digestive Endoscopy, The First Affiliated Hospital with Nanjing Medical University, 300 Guangzhou Road, 210029 Nanjing, Jiangsu, China
5 shared publicationsShijie Zhang
Digestive Endoscopy Department, The First Affiliated Hospital With Nanjing Medical University and Jiangsu Province Hospital, Nanjing, China
5 shared publications
Latest Publications
- 27 October 2026
- Published by Wiley in Advanced Functional Materials
State‐Instructive Apoptotic Body‐Mimetic Nanoparticles Reprogram Macrophages to Establish Antigen‐Specific Immune Tolerance in Celiac Disease
Celiac disease is an antigen‐driven autoimmune enteropathy characterized by a breakdown of gluten tolerance, yet current antigen‐delivering nanotherapies primarily focus on optimizing nanoparticle properties while overlooking the immunological state of antigen presenting cells (APCs). Here, we engineered apoptotic body‐mimetic gliadin nanoparticles (ABM‐G NPs) by incorporating phosphatidylserine (PS), an endogenous “eat‐me” signal, into a PLGA‐based gliadin delivery platform. ABM‐G NPs enhanced macrophage efferocytosis through PS‐dependent recognition, inducing a tolerogenic macrophage program characterized by metabolic remodeling and epigenetic reprogramming. Mechanistically, ABM‐G NPs promoted glycolytic flux and lactate accumulation, leading to H3K9 lactylation‐mediated activation of immune‐regulatory and metabolic genes, including Mrc1 and Hk1 . In gluten‐induced mouse models of celiac disease, ABM‐G NPs suppressed gliadin‐specific immune responses, promoted regulatory T cell expansion, and alleviated intestinal inflammation. This study establishes a state‐instructive biomaterial strategy that couples apoptotic mimicry with antigen delivery to achieve antigen‐specific immune tolerance.
- 27 October 2026
- Published by Wiley in Advanced Functional Materials
State‐Instructive Apoptotic Body‐Mimetic Nanoparticles Reprogram Macrophages to Establish Antigen‐Specific Immune Tolerance in Celiac Disease
Celiac disease is an antigen‐driven autoimmune enteropathy characterized by a breakdown of gluten tolerance, yet current antigen‐delivering nanotherapies primarily focus on optimizing nanoparticle properties while overlooking the immunological state of antigen presenting cells (APCs). Here, we engineered apoptotic body‐mimetic gliadin nanoparticles (ABM‐G NPs) by incorporating phosphatidylserine (PS), an endogenous “eat‐me” signal, into a PLGA‐based gliadin delivery platform. ABM‐G NPs enhanced macrophage efferocytosis through PS‐dependent recognition, inducing a tolerogenic macrophage program characterized by metabolic remodeling and epigenetic reprogramming. Mechanistically, ABM‐G NPs promoted glycolytic flux and lactate accumulation, leading to H3K9 lactylation‐mediated activation of immune‐regulatory and metabolic genes, including Mrc1 and Hk1 . In gluten‐induced mouse models of celiac disease, ABM‐G NPs suppressed gliadin‐specific immune responses, promoted regulatory T cell expansion, and alleviated intestinal inflammation. This study establishes a state‐instructive biomaterial strategy that couples apoptotic mimicry with antigen delivery to achieve antigen‐specific immune tolerance.
- 24 March 2026
- Published by Elsevier in Cancer Letters
- Vol. 647, 218446
Genome-wide CRISPR/Cas9 screen identified MCL1 as a senolytic target for clearing palbociclib-induced senescent and PD-L1-positive cells in colorectal cancer
- 24 March 2026
- Published by Elsevier in Cancer Letters
- Vol. 647, 218446
Genome-wide CRISPR/Cas9 screen identified MCL1 as a senolytic target for clearing palbociclib-induced senescent and PD-L1-positive cells in colorectal cancer
- Open Access
- 21 January 2026
- Published by Springer Nature in Oncogene
- Vol. 45 (5) , 664-666
Correction: CBX2 as a therapeutic target in colorectal cancer: insights into the altered chromatin accessibility via RUNX1-CBX2-MAP4K1 axis
- 21 January 2026
- Published by Springer Nature in Oncogene
- Vol. 45 (5) , 664-666
Open AccessCorrection: CBX2 as a therapeutic target in colorectal cancer: insights into the altered chromatin accessibility via RUNX1-CBX2-MAP4K1 axis
- 13 March 2025
- Published by Springer Nature in Oncogene
- Vol. 44 (13) , 909-926
CBX2 as a therapeutic target in colorectal cancer: insights into the altered chromatin accessibility via RUNX1-CBX2-MAP4K1 axis
Chromobox homolog 2 (CBX2), a component of the polycomb repressive complex 1, is overexpressed in various cancers, but its specific role in colorectal cancer (CRC) is not fully understood. This study aimed to characterize the functional and regulatory roles of CBX2 in CRC. Tissue microarray analysis revealed the elevated CBX2 levels in tumor compared to adjacent normal tissues, which is significantly correlated with poor prognosis. Gain and loss of function studies demonstrated that CBX2 significantly promoted CRC progression and chemoresistance in cell lines, patient-derived CRC organoids and xenografts. In the AOM/DSS mouse model, treatment with the innovatively-developed cy5-PBAE/siCBX2 nanoparticle significantly reduced tumor aggressiveness. Mechanistic studies unveiled that the transcription factor RUNX1 is the positive regulator of CBX2. RNA-seq, ATAC-seq and CUT & RUN results indicated CBX2 knockdown induced epigenetic changes, especially alterations in chromatin accessibility. Moreover, we further identified MAP4K1 as a target gene of RUNX1-CBX2, with significant clinical and prognostic relevance in CRC. Collectively, these findings suggest the pivotal role of RUNX1-CBX2-MAP4K1 axis in CRC progression and underscore CBX2 as a promising biomarker and therapeutic target. The regulatory function of CBX2 on chromatin accessibility and the role of the RUNX1-CBX2-MAP4K1-pERK axis in the progression of colorectal cancer.
- 13 March 2025
- Published by Springer Nature in Oncogene
- Vol. 44 (13) , 909-926
CBX2 as a therapeutic target in colorectal cancer: insights into the altered chromatin accessibility via RUNX1-CBX2-MAP4K1 axis
Chromobox homolog 2 (CBX2), a component of the polycomb repressive complex 1, is overexpressed in various cancers, but its specific role in colorectal cancer (CRC) is not fully understood. This study aimed to characterize the functional and regulatory roles of CBX2 in CRC. Tissue microarray analysis revealed the elevated CBX2 levels in tumor compared to adjacent normal tissues, which is significantly correlated with poor prognosis. Gain and loss of function studies demonstrated that CBX2 significantly promoted CRC progression and chemoresistance in cell lines, patient-derived CRC organoids and xenografts. In the AOM/DSS mouse model, treatment with the innovatively-developed cy5-PBAE/siCBX2 nanoparticle significantly reduced tumor aggressiveness. Mechanistic studies unveiled that the transcription factor RUNX1 is the positive regulator of CBX2. RNA-seq, ATAC-seq and CUT & RUN results indicated CBX2 knockdown induced epigenetic changes, especially alterations in chromatin accessibility. Moreover, we further identified MAP4K1 as a target gene of RUNX1-CBX2, with significant clinical and prognostic relevance in CRC. Collectively, these findings suggest the pivotal role of RUNX1-CBX2-MAP4K1 axis in CRC progression and underscore CBX2 as a promising biomarker and therapeutic target. The regulatory function of CBX2 on chromatin accessibility and the role of the RUNX1-CBX2-MAP4K1-pERK axis in the progression of colorectal cancer.
- 27 September 2024
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 56 (10) , 807-808
Revisiting the novel traction technique: the monorail method with clip-line traction
We are deeply impressed by the innovative article authored by Masashi Ono et al. [1], which introduces a novel traction technique for endoscopic submucosal dissection (ESD). This advanced approach significantly enhanced operational ease and flexibility for patients in whom complete resection was challenging. Compared with other traction methods, such as pulley traction [2], magnet-assisted traction [3], and endoluminal combined fixation traction [4], this technique notably minimizes gastrointestinal mucosal damage and simplifies coordination between the operator and assistant. Consequently, it diminishes the risk of surgical complications, prioritizing the patient’s health. However, we also have some concerns about the novel method. Firstly, the presented case involves a lesion located at the fundus dome of the stomach, an area that is notoriously difficult to access via gastroscopy. We wonder whether this method could also be applied to other challenging regions, such as the ileocecal junction. Secondly, we think the role of the monorail method in this case is more about encircling and resecting the lesion. It is our contention that for more complex or extensive lesions, this technique might exhibit certain limitations. It appears to be primarily effective in providing traction in a single direction, potentially lacking the versatility for multi-angle traction. Additionally, in cases involving fibrotic lesions, there might be concerns regarding insufficient traction force. Recent studies on gastric ESD traction for difficult cases highlighted the predominant use of combined traction methods for such lesions [5]. Therefore, it is advisable to conduct a comprehensive preoperative evaluation of the lesion’s location and carefully select the appropriate patient cohort before employing this technique. Finally, I harbor a slight apprehension regarding how to adjust the clipping position if it needs to be changed for directional adjustments during the operation. Will forcibly removing the clip damage the tissue and affect the quality of the pathological diagnosis? Article published online: 27 September 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 27 September 2024
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 56 (10) , 807-808
Revisiting the novel traction technique: the monorail method with clip-line traction
We are deeply impressed by the innovative article authored by Masashi Ono et al. [1], which introduces a novel traction technique for endoscopic submucosal dissection (ESD). This advanced approach significantly enhanced operational ease and flexibility for patients in whom complete resection was challenging. Compared with other traction methods, such as pulley traction [2], magnet-assisted traction [3], and endoluminal combined fixation traction [4], this technique notably minimizes gastrointestinal mucosal damage and simplifies coordination between the operator and assistant. Consequently, it diminishes the risk of surgical complications, prioritizing the patient’s health. However, we also have some concerns about the novel method. Firstly, the presented case involves a lesion located at the fundus dome of the stomach, an area that is notoriously difficult to access via gastroscopy. We wonder whether this method could also be applied to other challenging regions, such as the ileocecal junction. Secondly, we think the role of the monorail method in this case is more about encircling and resecting the lesion. It is our contention that for more complex or extensive lesions, this technique might exhibit certain limitations. It appears to be primarily effective in providing traction in a single direction, potentially lacking the versatility for multi-angle traction. Additionally, in cases involving fibrotic lesions, there might be concerns regarding insufficient traction force. Recent studies on gastric ESD traction for difficult cases highlighted the predominant use of combined traction methods for such lesions [5]. Therefore, it is advisable to conduct a comprehensive preoperative evaluation of the lesion’s location and carefully select the appropriate patient cohort before employing this technique. Finally, I harbor a slight apprehension regarding how to adjust the clipping position if it needs to be changed for directional adjustments during the operation. Will forcibly removing the clip damage the tissue and affect the quality of the pathological diagnosis? Article published online: 27 September 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 24 June 2024
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 274 (Pt 2) , 133304
Catalase catalyzed tannic acid-Fe3+ network coating: A theranostic strategy for intestinal barrier restoration
- 24 June 2024
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 274 (Pt 2) , 133304
Catalase catalyzed tannic acid-Fe3+ network coating: A theranostic strategy for intestinal barrier restoration
- 29 May 2024
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 56 (06) , 463-464
Endoscopic mucosal resection for challenging colonic mucosal lesions
We read the article by Uchima et al. that retrospectively analyzed a register of consecutive cap suction underwater endoscopic mucosal resection (UEMR) procedures, which facilitated the resection of flat lesions or those at the appendiceal orifice or ileocecal valve [11]. During UEMR, the mucosa and submucosa “float” away from the deeper muscularis layer, eliminating the need for submucosal injection [22]. In this article, the author employed cap suction to induce pseudopolyps from flat colon lesions. Similarly to band ligation EMR, the formation of a pseudopolyp following cap suction enables the direct excision of the lesion [33]. However, the process of prefilling the colonic lumen with water appears to be a laborious and time-consuming procedure. Given the failure of snares to capture flat lesions, we suggest employing a hybrid EMR procedure that incorporates endoscopic submucosal dissection (ESD) techniques for dissection of the circumferential mucosa of the lesion, followed by snare resection [44]. The hybrid EMR procedure not only facilitates effective lesion capture by anchoring the snare beneath the dissected mucosa, but also provides clear visualization of the lesion extent. The main advantage of UEMR is its technical ease; however, the en bloc resection rate and recurrence rate of UEMR for larger mucosal lesions are still not ideal compared with ESD [55]. We aspire to further exploration to promote the development of EMR. Article published online: 29 May 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 29 May 2024
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 56 (06) , 463-464
Endoscopic mucosal resection for challenging colonic mucosal lesions
We read the article by Uchima et al. that retrospectively analyzed a register of consecutive cap suction underwater endoscopic mucosal resection (UEMR) procedures, which facilitated the resection of flat lesions or those at the appendiceal orifice or ileocecal valve [11]. During UEMR, the mucosa and submucosa “float” away from the deeper muscularis layer, eliminating the need for submucosal injection [22]. In this article, the author employed cap suction to induce pseudopolyps from flat colon lesions. Similarly to band ligation EMR, the formation of a pseudopolyp following cap suction enables the direct excision of the lesion [33]. However, the process of prefilling the colonic lumen with water appears to be a laborious and time-consuming procedure. Given the failure of snares to capture flat lesions, we suggest employing a hybrid EMR procedure that incorporates endoscopic submucosal dissection (ESD) techniques for dissection of the circumferential mucosa of the lesion, followed by snare resection [44]. The hybrid EMR procedure not only facilitates effective lesion capture by anchoring the snare beneath the dissected mucosa, but also provides clear visualization of the lesion extent. The main advantage of UEMR is its technical ease; however, the en bloc resection rate and recurrence rate of UEMR for larger mucosal lesions are still not ideal compared with ESD [55]. We aspire to further exploration to promote the development of EMR. Article published online: 29 May 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- Open Access
- 21 May 2024
- Published by Elsevier in Photodiagnosis and Photodynamic Therapy
- Vol. 48, 104220
Moxifloxacin promotes two-photon microscopic imaging for discriminating different stages of DSS-induced colitis on mice
- 21 May 2024
- Published by Elsevier in Photodiagnosis and Photodynamic Therapy
- Vol. 48, 104220
Open AccessMoxifloxacin promotes two-photon microscopic imaging for discriminating different stages of DSS-induced colitis on mice
- 8 March 2024
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 31 (6) , 871-883
Identification of EGR4 as a prospective target for inhibiting tumor cell proliferation and a novel biomarker in colorectal cancer
EGR4 (Early Growth Response 4) is a member of the EGR family, involving in tumorigenesis. However, the function and action mechanism of EGR4 in the pathogenesis of colorectal cancer (CRC) remain unclear. To address this, we assessed the prognosis of CRC based on EGR4 using the Kaplan-Meier plotter tool and tissue microarray. The abundance of immunoinfiltration was evaluated through ssGSEA, TISIDB, and TIMER. In vitro experiments involving knockdown or overexpression of EGR4 were performed, and RNA-sequencing was conducted to explore potential mechanisms. Furthermore, we used oxaliplatin and 5-fluorouracil to validate the impact of EGR4 on chemo-resistance. Pan-cancer analysis and tissue microarray showed that EGR4 was highly expressed in CRC and significantly correlated with an unfavorable prognosis. Moreover, EGR4 expression was associated with immunoinfiltration and cancer-associated fibroblasts in the CRC microenvironment. Functional enrichment demonstrated that high-expressional EGR4 were involved in chromatin and nucleosome assembly. Additionally, EGR4 promoted the proliferation of CRC cells. Mechanistically, EGR4 upregulated TNFα to activate the NF-κB signaling pathway, and its knockdown reduced p65 nuclear translocation. Importantly, combining shEGR4 with oxaliplatin and 5-fluorouracil significantly inhibited CRC proliferation. Taken together, these findings provide new insights into the potential prognosis and therapeutic targets of EGR4 in CRC.
- 8 March 2024
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 31 (6) , 871-883
Identification of EGR4 as a prospective target for inhibiting tumor cell proliferation and a novel biomarker in colorectal cancer
EGR4 (Early Growth Response 4) is a member of the EGR family, involving in tumorigenesis. However, the function and action mechanism of EGR4 in the pathogenesis of colorectal cancer (CRC) remain unclear. To address this, we assessed the prognosis of CRC based on EGR4 using the Kaplan-Meier plotter tool and tissue microarray. The abundance of immunoinfiltration was evaluated through ssGSEA, TISIDB, and TIMER. In vitro experiments involving knockdown or overexpression of EGR4 were performed, and RNA-sequencing was conducted to explore potential mechanisms. Furthermore, we used oxaliplatin and 5-fluorouracil to validate the impact of EGR4 on chemo-resistance. Pan-cancer analysis and tissue microarray showed that EGR4 was highly expressed in CRC and significantly correlated with an unfavorable prognosis. Moreover, EGR4 expression was associated with immunoinfiltration and cancer-associated fibroblasts in the CRC microenvironment. Functional enrichment demonstrated that high-expressional EGR4 were involved in chromatin and nucleosome assembly. Additionally, EGR4 promoted the proliferation of CRC cells. Mechanistically, EGR4 upregulated TNFα to activate the NF-κB signaling pathway, and its knockdown reduced p65 nuclear translocation. Importantly, combining shEGR4 with oxaliplatin and 5-fluorouracil significantly inhibited CRC proliferation. Taken together, these findings provide new insights into the potential prognosis and therapeutic targets of EGR4 in CRC.
- Open Access
- 4 January 2024
- Published by Springer Nature in European Journal of Medical Research
- Vol. 29 (1) , 1-17
The impact of SLC10A3 on prognosis and immune microenvironment in colorectal adenocarcinoma
Background: SLC10A3, a gene upregulated in pan-cancer, lacks full understanding regarding its prognostic implications and association with immune infiltration in colorectal cancer (CRC). This study comprehensively analyzed SLC10A3 in CRC, evaluating its prognostic significance and influence on the tumor's immune microenvironment. Methods: Transcriptomic data from TCGA were obtained to compare SLC10A3 expression in both colorectal cancer (CRC) and normal tissues. Prognostic value was assessed for overall survival (OS), disease-specific survival (DSS), and progression-free interval (PFI). DNA methylation patterns of SLC10A3 and correlation with DNA mismatch repair (MMR) were explored. Genetic alterations in SLC10A3 were scrutinized. The study also delved into the influence of SLC10A3 on the immune microenvironment of CRC, including immune cell infiltration and chemokines. Involvement of cancer-associated fibroblasts (CAFs) was explored. Methylation status of specific CpG islands in the SLC10A3 gene correlated with CRC patient prognosis. CRC tissue microarray was performed to verify the expression of SLC10A3 and its relationship with prognosis. Results: The research revealed that SLC10A3 is significantly upregulated in CRC and holds promise as a potential diagnostic marker. Elevated SLC10A3 expression was linked to poorer OS, DSS, and PFI. Methylation patterns of SLC10A3 displayed prognostic relevance, and genetic alterations in the gene were identified. SLC10A3 was shown to impact the immune microenvironment, with significant correlations observed between its expression and various immune cell types, chemokines, and markers associated with CAFs. Furthermore, an inverse relationship between SLC10A3 and MMR molecules was established. Methylation status of specific CpG islands within the SLC10A3 gene was associated with CRC patient prognosis. Tissue microarray showed that SLC10A3 was highly expressed in CRC and significantly correlated with poor prognosis. Conclusion: The study underscores the importance of elevated SLC10A3 in CRC, associating it with decreased survival and immune infiltration, proposing it as a diagnostic biomarker and appealing immunotherapy target, given its significant overexpression and influence on the immune microenvironment and prognosis through methylation patterns. Graphical
- 4 January 2024
- Published by Springer Nature in European Journal of Medical Research
- Vol. 29 (1) , 1-17
Open AccessThe impact of SLC10A3 on prognosis and immune microenvironment in colorectal adenocarcinoma
Background: SLC10A3, a gene upregulated in pan-cancer, lacks full understanding regarding its prognostic implications and association with immune infiltration in colorectal cancer (CRC). This study comprehensively analyzed SLC10A3 in CRC, evaluating its prognostic significance and influence on the tumor's immune microenvironment. Methods: Transcriptomic data from TCGA were obtained to compare SLC10A3 expression in both colorectal cancer (CRC) and normal tissues. Prognostic value was assessed for overall survival (OS), disease-specific survival (DSS), and progression-free interval (PFI). DNA methylation patterns of SLC10A3 and correlation with DNA mismatch repair (MMR) were explored. Genetic alterations in SLC10A3 were scrutinized. The study also delved into the influence of SLC10A3 on the immune microenvironment of CRC, including immune cell infiltration and chemokines. Involvement of cancer-associated fibroblasts (CAFs) was explored. Methylation status of specific CpG islands in the SLC10A3 gene correlated with CRC patient prognosis. CRC tissue microarray was performed to verify the expression of SLC10A3 and its relationship with prognosis. Results: The research revealed that SLC10A3 is significantly upregulated in CRC and holds promise as a potential diagnostic marker. Elevated SLC10A3 expression was linked to poorer OS, DSS, and PFI. Methylation patterns of SLC10A3 displayed prognostic relevance, and genetic alterations in the gene were identified. SLC10A3 was shown to impact the immune microenvironment, with significant correlations observed between its expression and various immune cell types, chemokines, and markers associated with CAFs. Furthermore, an inverse relationship between SLC10A3 and MMR molecules was established. Methylation status of specific CpG islands within the SLC10A3 gene was associated with CRC patient prognosis. Tissue microarray showed that SLC10A3 was highly expressed in CRC and significantly correlated with poor prognosis. Conclusion: The study underscores the importance of elevated SLC10A3 in CRC, associating it with decreased survival and immune infiltration, proposing it as a diagnostic biomarker and appealing immunotherapy target, given its significant overexpression and influence on the immune microenvironment and prognosis through methylation patterns. Graphical